Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
, , , , , , y
14 ago 2022
Acerca de este artículo
Categoría del artículo: research article
Publicado en línea: 14 ago 2022
Páginas: 371 - 379
Recibido: 31 ene 2022
Aceptado: 07 abr 2022
DOI: https://doi.org/10.2478/raon-2022-0025
Palabras clave
© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Turnsek, Nina
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Devjak, Rok
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Edelbaher, Natalija
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Osrajnik, Ilonka
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Unk, Mojca
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Vidovic, Dusanka
Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Jeric, Tina
AstraZeneca UK Limited, Branch office in SloveniaLjubljana, Slovenia
Janzic, Urska
Department of Medical Oncology, University Clinic GolnikGolnik, Slovenia